Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Clinical and Economic Effectiveness of Influenza Vaccination in Older Adults

12 novembre 2026 mis à jour par: Thong Nhat Hospital

This study aims to evaluate the clinical and economic effectiveness of influenza vaccination among adults aged 60 years and older in Ho Chi Minh City, Vietnam. It will compare influenza-related health outcomes and healthcare costs between older adults who receive influenza vaccination and those who do not.

This is a prospective observational cohort study with a control group. The study plans to enroll 2,298 participants, including 766 vaccinated and 1,532 unvaccinated older adults. Participants will be recruited at Thong Nhat Hospital and University Medical Center Ho Chi Minh City. Vaccination status will be determined by participants' vaccination history and decisions made independently of the study.

Participants will be followed for 12 months, with follow-up assessments every three months. The study will collect information on influenza, influenza-like illness, cardiovascular events, respiratory events, hospitalization, mortality, and direct medical costs related to influenza.

The study will compare the occurrence of clinical outcomes and direct medical costs between the two groups. It will also evaluate economic measures related to influenza vaccination, including avoided treatment costs, cost savings, and the benefit-cost ratio. The findings will be used to provide scientific evidence for developing influenza vaccination policy recommendations for older adults in Ho Chi Minh City.

Aperçu de l'étude

Statut

Pas encore de recrutement

Intervention / Traitement

Description détaillée

Participants will be recruited using consecutive convenience sampling. Baseline information will be collected using standardized data collection forms, including demographic characteristics, medical history, underlying diseases, influenza vaccination status, and other relevant clinical information.

During follow-up, data will be collected through scheduled telephone contacts, community-based follow-up, and information obtained from healthcare facilities. Reported clinical events and healthcare utilization will be verified using available medical records and other relevant sources.

To address potential differences in baseline characteristics between the vaccinated and unvaccinated groups, the study will use statistical methods to control for confounding factors. Propensity score matching will be applied to improve comparability between the two groups. The clinical and economic effectiveness of influenza vaccination will be evaluated using the collected data.

Type d'étude

Observationnel

Inscription (Estimé)

2298

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Phan H Le, MD
  • Numéro de téléphone: +84 795 974 545
  • E-mail: lhphan@ump.edu.vn

Lieux d'étude

    • Ho Chi Minh City
      • Ho Chi Minh City, Ho Chi Minh City, Viêt Nam
        • Thong Nhat Hospital
        • Contact:
        • Contact:
      • Ho Chi Minh City, Ho Chi Minh City, Viêt Nam
        • University Medical Center Ho Chi Minh City
        • Contact:
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The study population comprises adults aged 60 years or older residing in Ho Chi Minh City, Vietnam. Participants will be recruited from two cohorts: older adults receiving one dose of influenza vaccine at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at enrollment, and unvaccinated older adults attending outpatient clinics at these hospitals who have not received influenza vaccination within the preceding 12 months. Participants will be selected using consecutive convenience sampling and followed for 12 months.

La description

Inclusion Criteria:

  • Adults aged 60 years or older residing in Ho Chi Minh City, Vietnam.

  • Belonging to one of the following two groups:

    • Vaccinated group: Older adults receiving one dose of influenza vaccine at the Vaccination Center of Thong Nhat Hospital or University Medical Center Ho Chi Minh City at the time of enrollment.
    • Unvaccinated control group: Older adults attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination within the preceding 12 months.
  • Having complete contact information and being able to be followed for 12 months through follow-up visits, telephone contact, and/or community-based follow-up.

  • Agreeing to participate in the study and providing written informed consent.

Exclusion Criteria:

  • Inability to accurately determine influenza vaccination status or the timing of influenza vaccination.
  • Refusal to participate in the study or withdrawal from the study during the prospective follow-up phase.
  • Participants in the unvaccinated control group who receive influenza vaccination during the 12-month follow-up period.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Influenza-Vaccinated Cohort

Adults aged 60 years or older who receive influenza vaccination at the vaccination centers of Thong Nhat Hospital or University Medical Center Ho Chi Minh City during the study period. The date of vaccination serves as the start of the 12-month follow-up period.

Influenza vaccination received as part of routine healthcare, independently of the study. Vaccination is not assigned or administered by the research team as a study intervention. Participants who receive influenza vaccination are included in the vaccinated cohort and followed for 12 months.

Unvaccinated Control Cohort

Adults aged 60 years or older attending outpatient clinics at Thong Nhat Hospital or University Medical Center Ho Chi Minh City who have not received influenza vaccination during the 12 months preceding enrollment. The enrollment date serves as the start of the 12-month follow-up period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Incidence of Confirmed Influenza
Délai: During the 12-month follow-up period

The proportion of participants with confirmed influenza during the 12-month follow-up period. Confirmed influenza is defined by a positive rapid influenza antigen test, a positive reverse transcription-polymerase chain reaction (RT-PCR) test, viral isolation, or a documented influenza diagnosis in the medical record, in accordance with the study protocol.

During the 12-month follow-up period
Incidence of Influenza-like Illness
Délai: During the 12-month follow-up period

The proportion of participants experiencing influenza-like illness (ILI) during the 12-month follow-up period. ILI is defined as an acute respiratory illness characterized by fever (measured body temperature of at least 38°C or self-reported fever or chills) accompanied by cough and/or sore throat, as specified in the study protocol.

During the 12-month follow-up period
Avoided Treatment Costs
Délai: Over the 12-month follow-up period

The estimated total treatment costs avoided through influenza vaccination over the 12-month follow-up period. Avoided treatment costs are calculated as the difference in mean treatment costs between the unvaccinated and vaccinated groups, multiplied by the number of vaccinated participants. Costs are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Net Cost Savings
Délai: Over the 12-month follow-up period

Net cost savings associated with influenza vaccination over the 12-month follow-up period, calculated as the total estimated treatment costs avoided minus the total vaccination costs, in accordance with the study protocol. Net cost savings are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Benefit-Cost Ratio
Délai: Over the 12-month follow-up period

The benefit-cost ratio of influenza vaccination over the 12-month follow-up period, calculated by dividing the total estimated treatment costs avoided by the total vaccination costs, as specified in the study protocol. The benefit-cost ratio is expressed as a dimensionless ratio.

Over the 12-month follow-up period

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of Respiratory Events
Délai: During the 12-month follow-up period

The proportion of participants experiencing respiratory events during the 12-month follow-up period. Respiratory events include bronchitis, pneumonia, acute exacerbations of chronic obstructive pulmonary disease, and acute exacerbations of asthma, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Cardiovascular Events
Délai: During the 12-month follow-up period

The proportion of participants experiencing cardiovascular events during the 12-month follow-up period. Cardiovascular events include acute myocardial infarction, acute stroke, and acute heart failure, as defined in the study protocol.

During the 12-month follow-up period
Incidence of Influenza-Related Hospitalization
Délai: During the 12-month follow-up period

The proportion of participants hospitalized during the 12-month follow-up period due to influenza, influenza-related conditions, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Influenza-Related Mortality
Délai: During the 12-month follow-up period

The proportion of participants who die during the 12-month follow-up period due to influenza, influenza-related causes, or complications of influenza, as defined in the study protocol.

During the 12-month follow-up period
Total Direct Medical Costs
Délai: Over the 12-month follow-up period

The total actual direct medical costs incurred during the 12-month follow-up period for the management of study-related clinical events. Costs are calculated by summing the actual medical expenditures associated with all relevant treatment episodes during follow-up and are expressed in Vietnamese dong (VND).

Over the 12-month follow-up period
Total Medical Costs Based on Health Insurance Rates
Délai: Over the 12-month follow-up period

The total medical costs associated with study-related clinical events during the 12-month follow-up period, calculated using the reimbursement rates specified by the Vietnamese health insurance system. Costs are summed across relevant treatment episodes and expressed in Vietnamese dong (VND).

Over the 12-month follow-up period

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Tan V Nguyen, PhD, Thong Nhat Hospital

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 janvier 2027

Achèvement primaire (Estimé)

1 mai 2028

Achèvement de l'étude (Estimé)

1 mai 2028

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

INDÉCIS

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner